Due to concern for increased bleeding risk, the “Moderate Pulmonary Embolism Treated with Thrombolysis” (MOPETT trial) was conducted using low-dose tissue plasminogen activator (tPA; 0.5 mg/kg with maximum dose of 50 mg). Here, PLAT is linked to pulmonary embolism.